Serum predominantly activates MAPK and akt kinases in EGFR- and ErbB2-over-expressing cells, respectively.
Tari
A M
AM
Lopez-Berestein
G
G
D001769:Blood; D001943:Breast Neoplasms / Q000201:enzymology / Q000378:metabolism; D004789:Enzyme Activation; D066246:ErbB Receptors / Q000235:genetics*; D015870:Gene Expression; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D014407:Tumor Cells, Cultured
D066246:ErbB Receptors; D020928:Mitogen-Activated Protein Kinases; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D051057:Proto-Oncogene Proteins c-akt; D018719:Erb-b2 Receptor Tyrosine Kinases; C494918:AKT1 protein, human